Andecaliximab

From WikiMD's WELLNESSPEDIA

Human monoclonal antibody


Overview[edit]

Andecaliximab is a monoclonal antibody that has been investigated for its potential use in the treatment of various diseases, including cancer and inflammatory diseases. It is specifically designed to target and inhibit the activity of matrix metalloproteinase 9 (MMP-9), an enzyme involved in the breakdown of the extracellular matrix and implicated in various pathological processes.

Mechanism of Action[edit]

Andecaliximab functions by binding to MMP-9, thereby inhibiting its enzymatic activity. MMP-9 is known to play a role in the degradation of the extracellular matrix, which is a critical process in tumor invasion and metastasis, as well as in inflammation. By inhibiting MMP-9, andecaliximab may help to prevent the progression of tumors and reduce inflammation.

Clinical Development[edit]

Andecaliximab has been evaluated in clinical trials for its efficacy and safety in treating various conditions. It has been studied in combination with other therapeutic agents, such as chemotherapy drugs, to assess its potential to enhance treatment outcomes.

Cancer[edit]

In the context of cancer, andecaliximab has been investigated for its ability to inhibit tumor growth and metastasis. Clinical trials have explored its use in combination with standard chemotherapy regimens in patients with advanced solid tumors.

Inflammatory Diseases[edit]

Andecaliximab has also been studied for its potential to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. By targeting MMP-9, it may help to reduce the inflammatory response and tissue damage associated with these conditions.

Safety and Efficacy[edit]

The safety and efficacy of andecaliximab have been evaluated in several clinical trials. Common side effects observed in these studies include fatigue, nausea, and diarrhea. The overall safety profile of andecaliximab is considered acceptable, with manageable adverse effects.

Future Directions[edit]

Research on andecaliximab continues to explore its potential applications in various therapeutic areas. Ongoing studies aim to better understand its mechanism of action, optimize dosing regimens, and identify patient populations that may benefit most from its use.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Andecaliximab&oldid=6534068"